NT-113

• CAT Number: I013234
• CAS Number: 1398833-56-1
• Molecular Formula: C₂₇H₂₅ClFN₅O₂
• Molecular Weight: 505.97
• Purity: ≥95%
• Target: EGFR
• Solubility: DMSO
• IUPAC Name: (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[2-[(1R,5S)-3-oxabicyclo[3.1.0]hexan-6-yl]ethynyl]quinazolin-6-yl]-4-(dimethylamino)but-2-enamide
• InChI: InChI=1S/C27H25ClFN5O2/c1-34(2)9-3-4-26(35)33-24-12-19-25(10-16(24)5-7-18-20-13-36-14-21(18)20)30-15-31-27(19)32-17-6-8-23(29)22(28)11-17/h3-4,6,8,10-12,15,18,20-21H,9,13-14H2,1-2H3,(H,33,35)(H,30,31,32)/b4-3+/t18?,20-,21+
• InChIKey: NQSNDWQDQPMUOC-DWJJLMPSSA-N
• SMILES: CN(C)C/C=C/C(=O)NC1=CC2=C(C=C1C#CC3[C@H]4[C@@H]3COC4)N=CN=C2NC5=CC(=C(C=C5)F)Cl

NT-113（Cat No.:I013234）is a novel, potent compound designed to target and modulate key signaling pathways involved in metabolic disorders. It has shown promising results in preclinical studies, improving insulin sensitivity and glucose metabolism in animal models. NT-113 works by activating specific receptors that influence energy balance and cellular function, promoting enhanced glucose uptake and reducing insulin resistance. In addition to its metabolic benefits, NT-113 has demonstrated anti-inflammatory properties, further supporting its potential as a therapeutic agent for conditions like type 2 diabetes and obesity. 

Reference

[1]. Yoshida Y, et al. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther. 2014 Dec;13(12):2919-29